Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals - PubMed (original) (raw)

Randomized Controlled Trial

Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals

Marjo Tuomainen et al. Nutr Diabetes. 2018.

Abstract

We recently reported using non-targeted metabolic profiling that serum indolepropionic acid (IPA), a microbial metabolite of tryptophan, was associated with a lower likelihood of developing type 2 diabetes (T2D). In the present study, we established a targeted quantitative method using liquid chromatography with mass spectrometric detection (HPLC-QQQ-MS/MS) and measured the serum concentrations of IPA in all the participants from the Finnish Diabetes Prevention Study (DPS), who had fasting serum samples available from the 1-year study follow-up (n = 209 lifestyle intervention and n = 206 control group). Higher IPA at 1-year study was inversely associated with the incidence of T2D (OR [CI]: 0.86 [0.73-0.99], P = 0.04) and tended to be directly associated with insulin secretion (β = 0.10, P = 0.06) during the mean 7-year follow-up. Moreover, IPA correlated positively with dietary fiber intake (g/day: r = 0.24, P = 1 × 10-6) and negatively with hsCRP concentrations at both sampling (r = - 0.22, P = 0.0001) and study follow-up (β = - 0.19, P = 0.001). Thus, we suggest that the putative effect of IPA on lowering T2D risk might be mediated by the interplay between dietary fiber intake and inflammation or by direct effect of IPA on β-cell function.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1

Scattered plot of the relationship of IPA concentrations (natural log transformed; ng/ml) measured from 1-year examination samples and a. average insulin secretion (DI30) during the mean seven years of follow-up in the DPS (β = 0.10, P = 0.06) and b. fiber intake (g/day) at IPA sampling (r = 0.24, P = 1 × 10−6). c. Association of indolepropionic acid (IPA) and hsCRP serum concentrations in DPS (n = 291). Descriptive figure of the course of serum hsCRP (natural log transformed; mg/L) during the active study follow-up since IPA sampling (yr 1) according to the median cut-off point in IPA. Solid line = above median cut-off; broken lines = below median cut-off. P = 0.008 for the difference between cut-off point groups

References

1. Global report on diabetes. 2016.
1. de Mello VD, et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study. Sci. Rep. 2017;7:46337. doi: 10.1038/srep46337. - DOI - PMC - PubMed
1. Wikoff WR, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc. Natl Acad. Sci. USA. 2009;106:3698–3703. doi: 10.1073/pnas.0812874106. - DOI - PMC - PubMed
1. Young SN, Anderson GM, Gauthier S, Purdy WC. The origin of indoleacetic acid and indolepropionic acid in rat and human cerebrospinal fluid. J. Neurochem. 1980;34:1087–1092. doi: 10.1111/j.1471-4159.1980.tb09944.x. - DOI - PubMed
1. Chimerel C, et al. Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep. 2014;9:1202–1208. doi: 10.1016/j.celrep.2014.10.032. - DOI - PMC - PubMed

Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals - PubMed (original) (raw)